Novo Nordisk A/S 2015 AR2
The report highlights Novo Nordisk's performance in 2015, showcasing an 8% sales growth and a 21% operating profit growth in local currencies. Key achievements include the US approval of Tresiba, the launch of Saxenda for obesity care, and the expansion of the Cities Changing Diabetes partnership. The company also announced a major 2 billion USD investment in production facilities in the US and Denmark. On the environmental front, Novo Nordisk reduced its CO2 emissions from energy consumption by 11% and committed to powering all production sites with 100% renewable electricity by 2020.
Company: Novo Nordisk A/S
Sector: Manufacturing
Country: Denmark
Year: 2015
Type: AR2
Pages: 116
Back to company
Novo Nordisk A/S
Annual Report
The report highlights Novo Nordisk's performance in 2015, showcasing an 8% sales growth and a 21% operating profit growth in local currencies. Key achievements include the US approval of Tresiba, the launch of Saxenda for obesity care, and the expansion of the Cities Changing Diabetes partnership. The company also announced a major 2 billion USD investment in production facilities in the US and Denmark. On the environmental front, Novo Nordisk reduced its CO2 emissions from energy consumption by 11% and committed to powering all production sites with 100% renewable electricity by 2020.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Women in Management
Workplace Fatalities
Employees